Your browser doesn't support javascript.
Residual Lung Abnormalities Following COVID-19 Hospitalization: Interim Analysis of the UKILD Post-COVID Study.
Stewart, Iain; Jacob, Joseph; George, Peter M; Molyneaux, Philip L; Porter, Joanna C; Allen, Richard J; Aslani, Shahab; Baillie, J Kenneth; Barratt, Shaney L; Beirne, Paul; Bianchi, Stephen M; Blaikley, John F; Chalmers, James D; Chambers, Rachel C; Chaudhuri, Nazia; Coleman, Christopher; Collier, Guilhem; Denneny, Emma K; Docherty, Annemarie; Elneima, Omer; Evans, Rachel A; Fabbri, Laura; Gibbons, Michael A; Gleeson, Fergus V; Gooptu, Bibek; Greening, Neil J; Guillen Guio, Beatriz; Hall, Ian P; Hanley, Neil A; Harris, Victoria; Harrison, Ewen M; Heightman, Melissa; Hillman, Toby E; Horsley, Alex; Houchen-Wolloff, Linzy; Jarrold, Ian; Johnson, Simon R; Jones, Mark G; Khan, Fasihul; Lawson, Rod; Leavy, Olivia; Lone, Nazir; Marks, Michael; McAuley, Hamish; Mehta, Puja; Parekh, Dhruv; Piper Hanley, Karen; Platé, Manuela; Pearl, John; Poinasamy, Krisnah.
  • Stewart I; Imperial College London, 4615, National Heart & Lung Institute, London, United Kingdom of Great Britain and Northern Ireland; iain.stewart@imperial.ac.uk.
  • Jacob J; University College London, 4919, Department of Respiratory Medicine, London, United Kingdom of Great Britain and Northern Ireland.
  • George PM; University College London, 4919, Centre for Medical Imaging & Computing, London, United Kingdom of Great Britain and Northern Ireland.
  • Molyneaux PL; Royal Brompton & Harefield NHS Foundation Trust, 4964, Interstitial Lung Disease Unit, London, United Kingdom of Great Britain and Northern Ireland.
  • Porter JC; Imperial College London, 4615, National Heart and Lung Institute, London, United Kingdom of Great Britain and Northern Ireland.
  • Allen RJ; Imperial College London, 4615, National Heart and Lung Institute, London, United Kingdom of Great Britain and Northern Ireland.
  • Aslani S; University College London, 4919, Centre for Inflammation and Tissue Repair, London, London, United Kingdom of Great Britain and Northern Ireland.
  • Baillie JK; University of Leicester, 4488, Department of Health Sciences, Leicester, Leicestershire, United Kingdom of Great Britain and Northern Ireland.
  • Barratt SL; University College London, 4919, Centre for Medical Imaging & Computing, London, United Kingdom of Great Britain and Northern Ireland.
  • Beirne P; The University of Edinburgh, 3124, Roslin Institute, Edinburgh, United Kingdom of Great Britain and Northern Ireland.
  • Bianchi SM; Royal Infirmary of Edinburgh, 59843, Intensive Care Unit, Edinburgh, United Kingdom of Great Britain and Northern Ireland.
  • Blaikley JF; North Bristol NHS Trust, 1982, Bristol Interstitial Lung Disease Service, Westbury on Trym, Bristol, United Kingdom of Great Britain and Northern Ireland.
  • Chalmers JD; Leeds Teaching Hospitals NHS Trust, 4472, Leeds, United Kingdom of Great Britain and Northern Ireland.
  • Chambers RC; Sheffield Teaching Hospitals NHS Foundation Trust, 7318, Academic Directorate of Respiratory Medicine, Sheffield, United Kingdom of Great Britain and Northern Ireland.
  • Chaudhuri N; The University of Manchester, 5292, Faculty of Biology Medicine and Health, Manchester, United Kingdom of Great Britain and Northern Ireland.
  • Coleman C; University Hospital of South Manchester NHS Foundation Trust, 5295, Manchester, United Kingdom of Great Britain and Northern Ireland.
  • Collier G; University of Dundee, 3042, Dundee, United Kingdom of Great Britain and Northern Ireland.
  • Denneny EK; University College London, 4919, Centre for Inflammation & Tissue Repair, Division of Medicine, London, United Kingdom of Great Britain and Northern Ireland.
  • Docherty A; Wythenshawe Hospital, 159812, Manchester, Greater Manchester, United Kingdom of Great Britain and Northern Ireland.
  • Elneima O; University of Nottingham, 6123, Nottingham, Nottinghamshire, United Kingdom of Great Britain and Northern Ireland.
  • Evans RA; The University of Sheffield, 7315, Imaging Sciences, Sheffield, United Kingdom of Great Britain and Northern Ireland.
  • Fabbri L; University College London, 4919, Centre for Inflammation &Tissue Repair, London, United Kingdom of Great Britain and Northern Ireland.
  • Gibbons MA; The University of Edinburgh, 3124, Critical Care, Edinburgh, United Kingdom of Great Britain and Northern Ireland.
  • Gleeson FV; University of Leicester, 4488, Leicester, Leicestershire, United Kingdom of Great Britain and Northern Ireland.
  • Gooptu B; University of Leicester, 4488, Leicester, Leicestershire, United Kingdom of Great Britain and Northern Ireland.
  • Greening NJ; Imperial College London, 4615, National Heart & Lung Institute, London, United Kingdom of Great Britain and Northern Ireland.
  • Guillen Guio B; University of Exeter Medical School, 171002, Institute of Biomedical & Clinical Science, Exeter, Devon, United Kingdom of Great Britain and Northern Ireland.
  • Hall IP; Royal Devon and Exeter NHS Foundation Trust, 9553, Respiratory Department, Exeter, Devon, United Kingdom of Great Britain and Northern Ireland.
  • Hanley NA; Oxford University Hospitals NHS Foundation Trust, 6397, Oxford, Oxfordshire, United Kingdom of Great Britain and Northern Ireland.
  • Harris V; University of Leicester, 4488, Leicester, Leicestershire, United Kingdom of Great Britain and Northern Ireland.
  • Harrison EM; University of Leicester, 4488, Department of Respiratory Sciences, Leicester, Leicestershire, United Kingdom of Great Britain and Northern Ireland.
  • Heightman M; University of Leicester, 4488, Leicester, Leicestershire, United Kingdom of Great Britain and Northern Ireland.
  • Hillman TE; University of Nottingham, 6123, Nottingham, United Kingdom of Great Britain and Northern Ireland.
  • Horsley A; NIHR Nottingham Biomedical Research Centre, 574111, Nottingham, Nottinghamshire, United Kingdom of Great Britain and Northern Ireland.
  • Houchen-Wolloff L; The University of Manchester, 5292, Manchester, United Kingdom of Great Britain and Northern Ireland.
  • Jarrold I; University Hospitals of Leicester NHS Trust, 4490, Leicester, United Kingdom of Great Britain and Northern Ireland.
  • Johnson SR; The University of Edinburgh Usher Institute of Population Health Sciences and Informatics, 172239, Edinburgh, United Kingdom of Great Britain and Northern Ireland.
  • Jones MG; University College London Hospitals NHS Foundation Trust, 8964, Interstitial Lung Disease Service, London, United Kingdom of Great Britain and Northern Ireland.
  • Khan F; University College London Hospitals NHS Foundation Trust, 8964, Department of Respiratory Medicine, London, United Kingdom of Great Britain and Northern Ireland.
  • Lawson R; The University of Manchester Faculty of Biology Medicine and Health, 12203, Division of Infection, Immunity and Respiratory Medicine, Manchester, United Kingdom of Great Britain and Northern Ireland.
  • Leavy O; Manchester University NHS Foundation Trust, 5293, Manchester Adult Cystic Fibrosis Centre, Manchester, United Kingdom of Great Britain and Northern Ireland.
  • Lone N; University Hospitals of Leicester NHS Trust, 4490, Leicester, United Kingdom of Great Britain and Northern Ireland.
  • Marks M; Asthma UK, 4831, British Lung Foundation, London, United Kingdom of Great Britain and Northern Ireland.
  • McAuley H; University of Nottingham, 6123, Division of Respiratory Medicine, Nottingham, Nottinghamshire, United Kingdom of Great Britain and Northern Ireland.
  • Mehta P; NIHR Nottingham Biomedical Research Centre, 574111, Nottingham, Nottinghamshire, United Kingdom of Great Britain and Northern Ireland.
  • Parekh D; University of Southampton, 7423, Respiratory Medicine, Southampton, Hampshire, United Kingdom of Great Britain and Northern Ireland.
  • Piper Hanley K; NIHR Nottingham Biomedical Research Centre, 574111, Division of Respiratory Medicine, Nottingham, Nottinghamshire, United Kingdom of Great Britain and Northern Ireland.
  • Platé M; Sheffield Teaching Hospitals NHS Foundation Trust, 7318, Sheffield, United Kingdom of Great Britain and Northern Ireland.
  • Pearl J; University of Leicester, 4488, Department of Health Sciences, Leicester, Leicestershire, United Kingdom of Great Britain and Northern Ireland.
  • Poinasamy K; The University of Edinburgh, 3124, Usher Institute, Edinburgh, United Kingdom of Great Britain and Northern Ireland.
Am J Respir Crit Care Med ; 2022 Dec 01.
Article in English | MEDLINE | ID: covidwho-2282594
ABSTRACT
RATIONALE Shared symptoms and genetic architecture between COVID-19 and lung fibrosis suggests SARS-CoV-2 infection may lead to progressive lung damage.

OBJECTIVES:

The UKILD Post-COVID study interim analysis was planned to estimate the prevalence of residual lung abnormalities in people hospitalized with COVID-19 based on risk strata.

METHODS:

The Post-HOSPitalisation COVID Study (PHOSP-COVID) was used for capture of routine and research follow-up within 240 days from discharge. Thoracic CTs linked by PHOSP-COVID identifiers were scored for percentage of residual lung abnormalities (ground glass opacities and reticulations). Risk factors in linked CT were estimated with Bayesian binomial regression and risk strata were generated. Numbers within strata were used to estimate post-hospitalization prevalence using Bayesian binomial distributions. Sensitivity analysis was restricted to participants with protocol driven research follow-up. MEASUREMENTS AND MAIN

RESULTS:

The interim cohort comprised 3700 people. Of 209 subjects with linked CTs (median 119 days, interquartile range 83-155), 166 people (79.4%) had >10% involvement of residual lung abnormalities. Risk factors included abnormal chest X-ray (RR 1·21 95%CrI 1·05; 1·40), percent predicted DLco<80% (RR 1·25 95%CrI 1·00; 1·56) and severe admission requiring ventilation support (RR 1·27 95%CrI 1·07; 1·55). In the remaining 3491 people, moderate to very-high risk of residual lung abnormalities was classified in 7·8%, post-hospitalization prevalence was estimated at 8.5% (95%CrI 7.6%; 9.5%) rising to 11.7% (95%CrI 10.3%; 13.1%) in sensitivity analysis.

CONCLUSIONS:

Residual lung abnormalities were estimated in up to 11% of people discharged following COVID-19 related hospitalization. Health services should monitor at-risk individuals to elucidate long-term functional implications. This article is open access and distributed under the terms of the Creative Commons Attribution 4.0 International License (https//creativecommons.org/licenses/by/4.0/).
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Language: English Journal subject: Critical Care Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Language: English Journal subject: Critical Care Year: 2022 Document Type: Article